{"doi":"10.1371/journal.pone.0329386","title":"Association of CSF visinin-like protein 1 levels with cerebral glucose metabolism among older adults","abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background</jats:title>\n<jats:p>CSF visinin-like protein 1 (VILIP-1) levels have exhibited potential utility as a marker of neuronal damage and are increased in Alzheimer’s disease (AD). The levels of CSF VILIP-1 have been associated with memory decline and hippocampal atrophy, while no studies have investigated the association between CSF VILIP-1 levels and cerebral glucose metabolism among older adults.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods</jats:title>\n<jats:p>Study participants had available baseline CSF VILIP-1 data and more than two assessments of 18-fluorodeoxyglucose positron emission tomography ([<jats:sup>18</jats:sup>F] FDG-PET) brain imaging. Linear mixed-effects models were used to examine the association between baseline CSF VILIP-1 levels and longitudinal changes in FDG-PET over time. Models were performed separately for the cognitively unimpaired (CU) and cognitively impaired (CI) participants.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results</jats:title>\n<jats:p>Among CU older adults, higher CSF VILIP-1 levels were marginally associated with a faster reduction in cerebral glucose metabolism. In CI older adults, CSF VILIP-1 levels were significantly associated with a faster reduction in cerebral glucose metabolism.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion</jats:title>\n<jats:p>These results provide novel insights into the relationship between neuronal injury and cerebral glucose metabolism, highlighting the potential of CSF VILIP-1 as a biomarker for monitoring and predicting the progression of neurodegenerative processes.</jats:p>\n</jats:sec>","journal":"PLOS One","year":2025,"id":608058,"datarank":0.10397207708399181,"base_score":0.6931471805599453,"endowment":0.6931471805599453,"self_citation_contribution":0.10397207708399181,"citation_network_contribution":0.0,"self_endowment_contribution":0.10397207708399181,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1561529,"name":"Sufeng Xiao","orcid":null,"position":1,"is_corresponding":false},{"id":1561531,"name":"Meiping Wan","orcid":"0009-0006-5511-9852","position":2,"is_corresponding":false},{"id":1561528,"name":"Zhaowei Wang","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Association of CSF visinin-like protein 1 levels with cerebral glucose metabolism among older adults","abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background</jats:title>\n<jats:p>CSF visinin-like protein 1 (VILIP-1) levels have exhibited potential utility as a marker of neuronal damage and are increased in Alzheimer’s disease (AD). The levels of CSF VILIP-1 have been associated with memory decline and hippocampal atrophy, while no studies have investigated the association between CSF VILIP-1 levels and cerebral glucose metabolism among older adults.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods</jats:title>\n<jats:p>Study participants had available baseline CSF VILIP-1 data and more than two assessments of 18-fluorodeoxyglucose positron emission tomography ([<jats:sup>18</jats:sup>F] FDG-PET) brain imaging. Linear mixed-effects models were used to examine the association between baseline CSF VILIP-1 levels and longitudinal changes in FDG-PET over time. Models were performed separately for the cognitively unimpaired (CU) and cognitively impaired (CI) participants.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results</jats:title>\n<jats:p>Among CU older adults, higher CSF VILIP-1 levels were marginally associated with a faster reduction in cerebral glucose metabolism. In CI older adults, CSF VILIP-1 levels were significantly associated with a faster reduction in cerebral glucose metabolism.</jats:p>\n</jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion</jats:title>\n<jats:p>These results provide novel insights into the relationship between neuronal injury and cerebral glucose metabolism, highlighting the potential of CSF VILIP-1 as a biomarker for monitoring and predicting the progression of neurodegenerative processes.</jats:p>\n</jats:sec>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40961040","pmcid":"PMC12443256","openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.1371/journal.pone.0329386","host_type":"publisher"},{"url":"https://dx.plos.org/10.1371/journal.pone.0329386","host_type":"publisher"},{"url":"https://doaj.org/article/1b21ee974d5440d4ba1546dca7a48a28","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12443256","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12443256/","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12443256","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12443256?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":["Brain","Humans","Alzheimer Disease","Fluorodeoxyglucose F18","Glucose","Positron-Emission Tomography","Aged","Aged, 80 and over","Middle Aged","Female","Male","Neurocalcin","Biomarkers","Cognitive Dysfunction"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-30T07:26:54.142803Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}